Literature DB >> 29665135

Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.

Francesca Romana Ponziani1, Sherrie Bhoori2, Chiara Castelli3, Lorenza Putignani4,5, Licia Rivoltini3, Federica Del Chierico4, Maurizio Sanguinetti6, Daniele Morelli7, Francesco Paroni Sterbini6, Valentina Petito1, Sofia Reddel4, Riccardo Calvani8, Chiara Camisaschi3, Anna Picca8, Alessandra Tuccitto3, Antonio Gasbarrini1, Maurizio Pompili1, Vincenzo Mazzaferro2.   

Abstract

The gut-liver axis plays a pivotal role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), which is the third leading cause of hepatocellular carcinoma (HCC) worldwide. However, the link between gut microbiota and hepatocarcinogenesis remains to be clarified. The aim of this study was to explore what features of the gut microbiota are associated with HCC in patients with cirrhosis and NAFLD. A consecutive series of patients with NAFLD-related cirrhosis and HCC (group 1, 21 patients), NAFLD-related cirrhosis without HCC (group 2, 20 patients), and healthy controls (group 3, 20 patients) was studied for gut microbiota profile, intestinal permeability, inflammatory status, and circulating mononuclear cells. We finally constructed a model depicting the most relevant correlations among these features, possibly involved in hepatocarcinogenesis. Patients with HCC showed increased levels of fecal calprotectin, while intestinal permeability was similar to patients with cirrhosis but without HCC. Plasma levels of interleukin 8 (IL8), IL13, chemokine (C-C motif) ligand (CCL) 3, CCL4, and CCL5 were higher in the HCC group and associated with an activated status of circulating monocytes. The fecal microbiota of the whole group of patients with cirrhosis showed higher abundance of Enterobacteriaceae and Streptococcus and a reduction in Akkermansia. Bacteroides and Ruminococcaceae were increased in the HCC group, while Bifidobacterium was reduced. Akkermansia and Bifidobacterium were inversely correlated with calprotectin concentration, which in turn was associated with humoral and cellular inflammatory markers. A similar behavior was also observed for Bacteroides.
Conclusion: Our results suggest that in patients with cirrhosis and NAFLD the gut microbiota profile and systemic inflammation are significantly correlated and can concur in the process of hepatocarcinogenesis.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2018        PMID: 29665135     DOI: 10.1002/hep.30036

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  143 in total

Review 1.  Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes.

Authors:  Michael Kriss; Elizabeth C Verna; Hugo R Rosen; Catherine A Lozupone
Journal:  Transplantation       Date:  2019-04       Impact factor: 4.939

2.  Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice.

Authors:  Shogo Takahashi; Yuhuan Luo; Suman Ranjit; Cen Xie; Andrew E Libby; David J Orlicky; Alexander Dvornikov; Xiaoxin X Wang; Komuraiah Myakala; Bryce A Jones; Kanchan Bhasin; Dong Wang; James L McManaman; Kristopher W Krausz; Enrico Gratton; Diana Ir; Charles E Robertson; Daniel N Frank; Frank J Gonzalez; Moshe Levi
Journal:  J Biol Chem       Date:  2020-02-19       Impact factor: 5.157

Review 3.  Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.

Authors:  Suzanne R Sharpton; Veeral Ajmera; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-07       Impact factor: 11.382

4.  Diabetes is associated with increased risk of hepatocellular carcinoma in non-alcoholic steatohepatitis with cirrhosis-implications for surveillance and future pharmacotherapy.

Authors:  Michael P Johnston; Janisha Patel; Christopher D Byrne
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

5.  Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome.

Authors:  Farzam Vaziri; Steven Colquhoun; Yu-Jui Yvonne Wan
Journal:  Liver Res       Date:  2020-10-17

Review 6.  Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome.

Authors:  Ziying Zhang; Haosheng Tang; Peng Chen; Hui Xie; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2019-10-12

7.  lncRNA MALAT1 binds chromatin remodeling subunit BRG1 to epigenetically promote inflammation-related hepatocellular carcinoma progression.

Authors:  Mingyan Huang; Huamin Wang; Xiang Hu; Xuetao Cao
Journal:  Oncoimmunology       Date:  2018-10-16       Impact factor: 8.110

8.  The potential association between periodontitis and non-alcoholic fatty liver disease: a systematic review.

Authors:  Mohammad Sultan Alakhali; Sadeq Ali Al-Maweri; Hashem Motahir Al-Shamiri; Khaled Al-Haddad; Esam Halboub
Journal:  Clin Oral Investig       Date:  2018-10-24       Impact factor: 3.573

Review 9.  Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

10.  Identification of biomarkers for physical frailty and sarcopenia through a new multi-marker approach: results from the BIOSPHERE study.

Authors:  Riccardo Calvani; Anna Picca; Federico Marini; Alessandra Biancolillo; Jacopo Gervasoni; Silvia Persichilli; Aniello Primiano; Hélio J Coelho-Junior; Matteo Cesari; Maurizio Bossola; Andrea Urbani; Graziano Onder; Francesco Landi; Roberto Bernabei; Emanuele Marzetti
Journal:  Geroscience       Date:  2020-06-01       Impact factor: 7.713

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.